STELLARA Scores High at FHS

Published Online: Saturday, April 1, 2006

STELLARA Clinical Intervention and Patient Monitoring software, powered by the TheraDoc Expert System Platform, showed a significant cost savings and reduction of adverse drug events (ADEs) at Franciscan Health System (FHS), according to a 6-month study completed at the Tacoma, Wash-based health system. From July 2004 to June 2005, FHS pharmacy management tracked the number of medication orders and the staff's productivity for 6 months prior to STELLARA's implementation, compared with the first 6 months post-implementation.

"We have experienced tremendous success with STELLARA as our intelligent interface software over the past year, which led to an increase in clinical interventions by our pharmacists," said J. Kelly Martin, PharmD, director of pharmaceutical services at FHS. "We are seeing concrete results in the forms of cost savings and improved patient care. In 2005, cost savings from interventions increased by 23%, and our pharmacists prevented 222 ADEs (a 23% increase from 2004) after implementation of STELLARA. Interventions made by pharmacists increased from 17,906 to 27,667—a 55% increase."

Manufactured by bioMérieux Inc, the STELLARA system provides knowledgeenriched, infectious disease-specific recommendations to clinicians for medication treatment management. The company recently completed its suite of Intelligent Patient Therapy Software Systems, allowing the clinician to capture a more thorough view of the patient, preventing potential medication errors, and decreasing the chances of costly ADEs.

Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues